
Symposium
“Excellence in Medicinal Chemistry Symposium”
Honoring Nick Meanwell.
Organized by the Medicinal Chemistry Section
of the Northeastern Section, American Chemical Society (NESACS)

Nick Meanwell
BMS (Retired)
Thursday – December 8th, 2022
Takeda Cambridge
35 Lansdowne Street, Cambridge Massachusetts 02139
3:00 pm – Refreshments
3:15 pm – Welcome by Raj Rajur, Medicinal Chemistry Program Chair
CreaGen, Woburn, MA
3:20 pm – Introductory Remarks (Moderator) by Paul Greenspan
Takeda, Cambridge, MA
3:30 pm – 4:15 pm – Dylan England, Ph.D.
Takeda, Cambridge, MA
Title: “Discovery of TAK-981, Subasumstat, a First in Class Inhibitor of Sumo Activating Enzyme (SAE)”
4:15 pm – 5:00 pm – Michelle Garnsey, Ph.D.
Pfizer, Cambridge, MA
Title: “Discovery of the MC4R antagonist PF-07258669 as a potential treatment for appetite loss”
5:00 pm – 5:45 pm – David Candito, Ph.D.
Merck Research Laboratories, Boston, MA
Title: “Discovery and Optimization of Potent, Selective and Brain Penetrant LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease.”
6:00 pm – 6:45 pm – Social Hour
6:45 pm – 7:45 pm – Dinner
7:45 pm – 8:30 pm – Keynote Presentation by Nick Meanwell, Ph.D.
Bristol Myers Squibb (retired), Cambridge, MA
Title: “Inhibitors of HIV-1 Maturation”
Symposium Organizing Committee: Brian Aquila, Mark Ashwell, Scott Edmondson, Dan Elbaum, Paul Greenspan, Adrian Hobson, Peter Fuller, Mala Gopalsamy, Blaise Lippa, Lisa Marcaurelle, Kap-Sun Yeung, Sara Buhrlage Andrew Scholte, Raj (SB) Rajur.
Pictures from the event
- First talk by Dylan England
- Synthasis of TAK-981 (subasumstat)
- 2nd talk by Michelle Garnsey
- Conversation at dinner
- Drs. Paul Greenspan, Brian Aquila, and Nicholas A. Meanwell
- Dr. Meanwell easing into his talk.
- The HIV-1 Maturation Process, Role of IP6